Dynavax reported a 16% year-over-year increase in total revenues, reaching $80.6 million, with HEPLISAV-B net product revenue growing by 27% to $79.3 million. The company's net income was $17.6 million, or $0.13 per share basic and $0.12 diluted. They also announced a $200 million share repurchase program and discontinued the Tdap-1018 program to focus on long-term value creation.
HEPLISAV-B quarterly net product revenue reached $79.3 million, a 27% year-over-year increase.
The hepatitis B adult vaccine market is expected to expand to over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% market share.
Dynavax expects to achieve positive net income for the full year 2024, indicating full-year profitability.
The company's cash position strengthened to $764 million in Q3 2024.
Dynavax updated its full year 2024 financial guidance, based on the Company’s current operating plan.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance